Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1117568 in Adults with Schizophrenia

NBI-1117568 is an Investigational, First-in-Class, Muscarinic M4 Selective Agonist SAN DIEGO, Oct. 27, 2022 /PRNewswire/ — Neurocrine Biosciences, Inc. (Nasdaq: NBIX), a leading neuroscience-focused biopharmaceutical company, today announced the first patient has been randomized for its…

Click here to view original post

ADVERTISEMENT — Advertise With Biotech Networks